Systemic Bevacizumab (Avastin) for Juvenile‐Onset Recurrent Respiratory Papillomatosis: A Systematic Review
Authors:
- 22 September 2020
- journal article
- review article
- Published by Wiley in The Laryngoscope
- Vol. 131 (5) , 1138-1146
Abstract
Objectives: Juvenile onset recurrent respiratory papillomatosis (JORRP) can cause severe or disseminated disease. Surgical treatment may be inadequate. Systemic bevacizumab has shown initial success for severe JORRP. The objective of this systematic review was to assess usage, effectiveness, and safety of this treatment.Methods: We searched PubMed, Embase, and Web of Science for studies of humans with JORRP treated with systemic bevacizumab. Two researchers independently reviewed the studies to determine inclusion and aggregate data on patient characteristics, dosing protocols, treatment response, adverse events, and level of evidence.Results: Of 80 identified articles, 12 studies were included detailing 20 distinct cases. At a mean age of 12.8 years (range = 1–43 years) patients received initial dosing of 5 to 10 mg/kg of bevacizumab followed by ongoing doses at a mean 3‐week intervals (range = 2–5 weeks). All patients had clinically significant disease reduction with reduced need for surgery. Six patients (30%) had complete response in at least one involved anatomic site. Eleven (55%) required no surgery after initiating treatment. There was recurrence in all four patients whose treatment was stopped, but had rapid improvement with treatment resumption. Six (30%) experienced mild or moderate adverse events.Conclusions: Marked improvement in severe JORRP has been reported from systemic bevacizumab. Treatment protocols vary, and treatment discontinuation was not feasible in any reported patient. Based on currently available data, systemic bevacizumab can be considered for severe JORRP as it appears to be well tolerated and effective. A clinical trial could enhance the understanding of its safety and efficacy for this indication. Laryngoscope, 131:1138–1146, 2021Keywords
This publication has 28 references indexed in Scilit:
- Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosisOncology Letters, 2014
- Estimating the Incidence and Prevalence of Juvenile-Onset Recurrent Respiratory Papillomatosis in Publicly and Privately Insured Claims Databases in the United StatesSexually Transmitted Diseases, 2014
- The natural history of human papillomavirus infections of the mucosal epitheliaAPMIS, 2010
- The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national databaseThe Laryngoscope, 2010
- Regression of Recurrent Respiratory Papillomatosis With Celecoxib and Erlotinib Combination TherapyChest, 2009
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysisThe Lancet Oncology, 2009
- Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experienceOtolaryngology–Head and Neck Surgery, 2005
- Clinical Course of Recurrent Respiratory Papillomatosis in Danish ChildrenJAMA Otolaryngology–Head & Neck Surgery, 2004
- Indole-3-Carbinol for recurrent respiratory papillomatosis: long-term resultsJournal of Voice, 2004
- Can Mumps Vaccine Induce Remission in Recurrent Respiratory Papilloma?JAMA Otolaryngology–Head & Neck Surgery, 2002